Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Momelotinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    GSK in breach for misleading prescription information on Omjjara
    GSK in breach for misleading prescription information on Omjjara

    16 Apr 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-breach-misleading-prescribing-information-omjjara-industry-body-says-2025-04-15/

    REUTERS
    16 Apr 2025
    Share Share
    GSK’s Omjjara Receives Japanese Approval For Myelofibrosis Treatment
    GSK’s Omjjara Receives Japanese Approval For Myelofibrosis Treatment

    25 Jun 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=169944&sid=2

    PHARMABIZ
    25 Jun 2024
    Share Share
    European Commission authorises GSK’s Omjjara (momelotinib)
    European Commission authorises GSK’s Omjjara (momelotinib)

    29 Jan 2024

    // PRESS RELEASE

    https://www.gsk.com/en-gb/media/press-releases/european-commission-authorises-gsk-s-omjjara-momelotinib/

    PRESS RELEASE
    29 Jan 2024
    Share Share
    OJJAARA™ (momelotinib) Now Available from Onco360 For MF
    OJJAARA™ (momelotinib) Now Available from Onco360 For MF

    25 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230925017627/en

    BUSINESSWIRE
    25 Sep 2023
    Share Share
    US FDA approves GSK's bone marrow cancer therapy
    US FDA approves GSK's bone marrow cancer therapy

    16 Sep 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-gsks-anemia-treatment-2023-09-15/

    REUTERS
    16 Sep 2023
    Share Share
    Combination Therapies May Spur Evolution of the Myelofibrosis Treatment Paradigm
    Combination Therapies May Spur Evolution of the Myelofibrosis Treatment Paradigm

    22 Jun 2023

    // Ruxolitinib ONCLIVE

    https://www.onclive.com/view/combination-therapies-may-spur-evolution-of-the-myelofibrosis-treatment-paradigm

    Ruxolitinib ONCLIVE
    22 Jun 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.